The Pharma Data

JANUARY 17, 2021

This coverage provides a minimally invasive treatment alternative for eligible patients. “Not being able to breathe really limits the ability of patients to go about their daily lives, and for those who qualify for the treatment, endobronchial valves can make a big difference.” . CENTER VALLEY, Pa. ,

Treatment 52

Treatment Clinical Trials Trials Disease 52

PPD

OCTOBER 31, 2024

2024 trends with momentum Personalized/precision medicine: Tailoring treatments to individual genetic profiles and specific patient characteristics is becoming increasingly important. This aims to ensure that treatments are effective across varied demographics and to address historical gaps in clinical research.

Drug Development 52

Drug Development Clinical Trials Trials Drugs 52

Fierce BioTech

AUGUST 14, 2024

Epilepsy Clinical Trials Finding an effective epilepsy treatment can be arduous. Download this brochure to delve into how IQVIA's expertise and innovative strategic approach can streamline the clinical trial process, helping to get new therapies to patients who need them sooner.

Clinical Trials 52

Clinical Trials Trials Therapies Treatment 52

Alta Sciences

NOVEMBER 4, 2024

Download a copy of this case study. Product Disposal: We disposed of all waste and material generated from the manufacturing loteprednol etabonate at regulated chemical treatment facilities. Loteprednol etabonate, a corticosteroid, requires stringent safety protocols due to its classification as a highly potent API.

Engineering 52

Engineering Production Compliance Laboratories 52

The Pharma Data

JANUARY 12, 2021

a biopharmaceutical company focused on the development of first-in-class therapeutics for the treatment of cancer, today announced the completion of the Phase 1b clinical trial conducted by the NCI with its lead clinical candidate zotiraciclib (ZTR/TG02), a potent oral cyclin-dependent kinase 9 (CDK9) inhibitor. .

Clinical Trials 52

Clinical Trials Trials Treatment Pharmaceuticals 52

The Pharma Data

JANUARY 17, 2021

a biopharmaceutical company engaged in the discovery and development of RNAi therapeutics against cancer and fibrotic diseases, today announced dose administration for the first patient in a Phase 2a clinical study of the company’s lead drug candidate, STP705, for the treatment of cutaneous basal cell carcinoma. GAITHERSBURG, Md.

Treatment 52

Treatment Trials FDA Approval RNA 52

Broad Institute

JUNE 14, 2024

But when postdoctoral researcher and study first author Sean Misek joined Boehm’s and Beroukhim’s labs in 2020, he wanted to know how germline genetic variants — which are inherited and in all cells throughout the body — influence how tumors respond to treatment. In particular, he saw these effects in CRISPR guides. “We

Drugs 145

Drugs RNA DNA Research 145

DrugBank

AUGUST 20, 2024

It’s designed to equip you with the knowledge and tools needed to navigate the complexities of undruggable targets, harness the power of biotechnology, and ultimately bring life-saving treatments to patients faster.   Download Unlocking Undruggable Targets: Biotechnology’s Role in Expanding Drug Discovery today.

Therapies 98

Therapies Pharmaceuticals Disease Research 98

Predictive Oncology

JULY 26, 2024

EndoPrep as a sample treatment system to be used with FUJIFILM PYROSTAR ES-F/Plate Download white paper here Interested in partnering with us? Please fill out the form below. appeared first on Predictive Oncology.

Treatment 52

Treatment 52

The Pharma Data

DECEMBER 20, 2020

20 , 2020 /PRNewswire/ — The broad spectrum antiviral therapeutic, ‘hzVSF-v13(humanized Virus Suppressing Factor)’ being developed by ImmuneMed , is on track to progress as a treatment for the COVID-19 pneumonia patients. View original content to download multimedia: [link]. CHUNCHEON, South Korea , Dec.

Clinical Trials 40

Clinical Trials Treatment Trials Hospitals 40

The Pharma Data

OCTOBER 25, 2020

for the treatment of severe vernal keratoconjunctivitis (VKC) in patients ages 4-18. “We look forward to working with the FDA during the review process and are optimistic this treatment could provide much needed symptom relief for those affected so they may better engage in their daily activities.” .

Treatment 52

Treatment FDA Pharmaceuticals Clinical Trials 52

Fierce BioTech

MAY 29, 2024

Characterizing these products and developing robust manufacturing processes can help to usher them to market and provide new treatment options for diseases which are currently challenging to treat. png Sat, 06/01/2024 - 09:00 Biotech Biotech Landing Page Url Download Now Byline Sponsored by: Lonza Read this white paper to learn more.

Treatment 52

Treatment Disease Marketing Production 52

Drug Target Review

JULY 31, 2023

By exploring the latest advancements and potential treatment approaches for their areas of interest, readers can deepen their understanding of disease-specific applications. Please click download to access this FREE resource.

Therapies 98

Therapies Disease Clinical Development Hospitals 98

PPD

SEPTEMBER 25, 2023

Historically, clinical trial populations were almost exclusively comprised of white, male participants,  exacerbating gaps in knowledge of diseases and conditions , preventive factors and treatment effectiveness. DOWNLOAD THE FULL REPORT The post New Report Reveals Trends, Opportunities in Drug Development appeared first on PPD Inc.

Drug Development 104

Drug Development Clinical Trials Drugs Trials 104

Fierce BioTech

OCTOBER 2, 2023

Logistics For Cell & Gene Therapy Trials: Specific Needs Demand Special Skills Download now to learn more about intricate trial logistics, the importance of expertise, navigating regulations, secure data management, and real case studies like viral vector therapy for Spinal Muscular Atrophy. A specialized provider is essential.

Therapies 52

Therapies Trials Regulations Disease 52

The Pharma Data

NOVEMBER 26, 2020

Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) date for review of the Company’s Biologics License Application (BLA) seeking accelerated approval of pegunigalsidase alfa (PRX–102) for the proposed treatment of adult patients with Fabry disease. About Pegunigalsidase Alfa.

Disease 52

Disease Treatment Clinical Trials FDA 52

The Pharma Data

SEPTEMBER 15, 2020

Download Your Copy. We respect your privacy, by clicking “Download Your Copy” you will receive our e-newsletter, including information on Podcasts, Webinars, event discounts, online learning opportunities and agree to our User Agreement. Download Your Copy. Add bookmark. You can unsubscribe at any time.

Regulations 52

Regulations Production Therapies Treatment 52

The Pharma Data

NOVEMBER 26, 2020

Download Your Copy. We respect your privacy, by clicking “Download Your Copy” you agree to having your details passed onto the sponsor who may promote similar products and services related to your area of interest subject to their privacy policy. . Download Your Copy. . Download Your Copy.

Clinical Trials 52

Clinical Trials Marketing Trials Clinical Supply 52

Fierce BioTech

NOVEMBER 16, 2023

This insightful whitepaper explores the combination of exosomal RNA (exoRNA) and cfDNA in cancer diagnosis and treatment. Download now. This insightful whitepaper explores the combination of exosomal RNA (exoRNA) and cfDNA in cancer diagnosis and treatment.

RNA 52

RNA DNA Therapies Treatment 52

The Pharma Data

JANUARY 13, 2021

Food and Drug Administration (FDA) has designated as a Fast Track development program the investigation of Brilacidin as a potential treatment for COVID-19. A molecular screening study of 11,552 compounds also supports Brilacidin as a promising novel coronavirus treatment. WAKEFIELD, Mass.,

Clinical Trials 52

Clinical Trials Trials Treatment Pharmaceuticals 52

The Pharma Data

JANUARY 27, 2021

HK), announced today that China Center for Drug Evaluation (CDE) has granted Breakthrough Therapy designation to Batoclimab (HBM 9161), a fully human anti-FcRn monoclonal antibody (mAb), for the treatment of adult patients with Myasthenia Gravis (MG). View original content to download multimedia: [link]. CAMBRIDGE, Mass.

Therapies 40

Therapies Treatment International Licensing 40

Fierce BioTech

JUNE 1, 2023

Download the white paper to learn more about the diagnostic potential of antibodies. mteefey Thu, 06/01/2023 - 16:16 Autoantibody screening is promising for early cancer detection with the potential to improve the whole treatment decision tree, providing a less invasive, powerful approach. Seniorlink, Inc.

Treatment 52

Treatment Production Research 52

Fierce BioTech

AUGUST 15, 2024

Mining Unstructured EHR Data: Generate more effective real-world evidence by accessing the language of clinicians Download now to discover: • The treatment-related insights you can find in unstructured textual data • How pharma can benefit from more contextual patient information • Why clinician and data scientist oversight is critical for precise (..)

Treatment 40

Treatment 40

Fierce BioTech

JULY 25, 2023

How combining datasets from multiple sources can inform and improve commercial strategies Hundreds of rare disease treatments have entered the market over the past decade—thanks largely to a combination of government incentives, strong urging from patient advocacy groups and advances in cell and gene therapies.

Pharma Companies 52

Pharma Companies Government Therapies Disease 52

Fierce BioTech

OCTOBER 19, 2023

Download Now. Cerba Research cancer treatments drug development gene therapy Resource Type Whitepaper Cerba Logo.png Thu, 10/19/2023 - 09:39 Biotech Biotech Research Fierce Biotech Landing Page Url [link] Byline Sponsored by: Cerba Research

Therapies 52

Therapies Drug Development Treatment Research 52

The Pharma Data

OCTOBER 20, 2020

We created the first and only approved treatment for children and adults with spinal muscular atrophy as well as the world’s first RNA-targeted therapeutic approved for the treatment of polyneuropathy in adults with hereditary transthyretin amyloidosis. View original content to download multimedia: [link]. Source link.

RNA 52

RNA Pharmaceuticals Disease Treatment 52

Conversations in Drug Development Trends

JUNE 13, 2024

This groundbreaking approach can help tailor medical treatments to an individual’s genetic makeup, considerably enhancing drug efficacy and safety while minimizing adverse drug reactions. Pharmacogenomics (PGx), the study of how genes affect a person’s response to drugs, has brought significant changes to the clinical trial industry.

DNA 72

DNA Compliance Clinical Trials Trials 72

The ChEMBL-og

MARCH 8, 2023

ChEMBL contains information on drugs that have been approved for treatment of a specific disease / diagnosis (an indication) within a region of the world (e.g. NEVANIMIBE HYDROCHLORIDE ( CHEMBL542103 ) is under clinical investigation for treatment of Cushing syndrome at Phase 2.

Clinical Trials 40

Clinical Trials FDA Approval Trials Treatment 40

The Pharma Data

JANUARY 31, 2021

1, 2021 /PRNewswire/ — Nevro Corp (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced that D. View original content to download multimedia: [link]. . REDWOOD CITY, Calif. , .

Therapies 52

Therapies Treatment Production 52

The Pharma Data

JANUARY 7, 2021

– January 8, 2021) – Notable Labs, which is redefining cancer treatment by taking a functional approach to precision oncology in hematological cancers, today announced that it is participating in Biotech Showcase 2021 and will be presenting the strategic plan for long-term growth. Foster City, California–(Newsfile Corp.

Pharmaceutical Companies 52

Pharmaceutical Companies Therapies Science Pharmaceuticals 52

DrugBank

OCTOBER 19, 2022

As a result, we have created a more targeted list of suggested treatment alternatives through the use of more accurate therapeutic categorization. Download your Guide to Quality Drug Data Available for All Clinical API Users These latest features are available for all our Clinical API users. Download your Guide to Quality Drug Data

Drugs 52

Drugs Treatment 52

The Pharma Data

DECEMBER 28, 2020

“No woman should suffer these in silence because treatment is available,” said Rajal Patel , MD. “No woman should suffer these in silence because treatment is available. View original content to download multimedia: [link]. I’m here and I’m excited to help.” SOURCE Northwestern Medicine.

Doctors 52

Doctors Treatment International Disease 52

PPD

DECEMBER 16, 2024

The impact of lengthening timelines Ballooning timelines in clinical trials have a profound impact on drug development, driving up operational costs and delaying market access for promising new treatments. Download the full report The post The Real Cost of Complexity: What Every Drug Developer Needs to Know appeared first on PPD.

Drug Development 52

Drug Development Clinical Trials Compliance Trials 52

The Pharma Data

JANUARY 6, 2021

7, 2021 /PRNewswire/ — UNION therapeutics A/S ( UNION ) today announces that the US Food and Drug Administration (FDA) has approved an Investigational New Drug program (IND) for oral orismilast; a next generation PDE4-inhibitor for the treatment of plaque psoriasis in adults. One step closer to a novel treatment. Source link.

FDA Approval 52

FDA Approval FDA Clinical Development Treatment 52

The Pharma Data

OCTOBER 20, 2020

Melflufen (INN melphalan flufenamide) is in development as a new treatment for the hematological malignancy multiple myeloma and is currently being tested in multiple clinical studies including the pivotal phase 2 HORIZON study and the ongoing phase 3 OCEAN study. The following files are available for download: View original content: [link].

Pharmaceutical Companies 52

Pharmaceutical Companies Treatment FDA Therapies 52

The Pharma Data

NOVEMBER 25, 2020

26, 2020 /PRNewswire/ — Cantargia AB (OMXS: CANTA) and BioInvent International AB (OMXS: BINV), today announced that BioInvent has been contracted as manufacturer of Cantargia’s antibody CAN10 in preclinical development for the treatment of systemic sclerosis and myocarditis. LUND, Sweden , Nov. About Cantargia.

Clinical Trials 52

Clinical Trials Licensing Licensing International 52

The Pharma Data

DECEMBER 21, 2020

Extension eliminates out-of-pocket costs for treatment, allowing impacted members to focus on health and recovery for as long as the public health emergency lasts. View original content to download multimedia: [link]. OAKLAND, Calif. , 22, 2020 /PRNewswire/ — With new cases surging throughout the U.S, OAKLAND, Calif. ,

Virus 52

Virus Clinical Research Treatment Disease 52